Brazil SUS to Offer Twice-Yearly HIV Prevention Shot Lenacapavir
Health · Brazil
Key Facts
—The drug. Brazil is moving to add lenacapavir, a long-acting HIV-prevention injection, to its public health system.
—How it works. Lenacapavir is given as a subcutaneous injection just twice a year, replacing a daily pill.
—The approval. Health regulator Anvisa approved the drug in January 2026 for adults and adolescents over 12 who weigh at least 35 kg.
—The evidence. Trials showed near-total protection against HIV, and far better results than daily oral PrEP.
—The hurdle. Adding it to the SUS still depends on a price ceiling and a formal cost-effectiveness review.
Brazil is taking a major step toward offering one of the most powerful HIV-prevention tools yet through its free public health system. The country is weighing how to add lenacapavir, a twice-yearly injection, to the SUS.
A twice-a-year shield against HIV
Lenacapavir is a long-acting form of pre-exposure prophylaxis, or PrEP, the medicine that prevents HIV infection. Instead of a daily pill, it is given as a subcutaneous injection only once every six months. That simplicity is expected to sharply improve adherence, the main weakness of daily oral PrEP.
For people at higher risk of HIV, two clinic visits a year could replace the burden of remembering a pill each day. Public-health experts see long-acting PrEP as a potential turning point in the fight against the epidemic.
To understand why this matters, it helps to know that daily oral PrEP has been available in Brazil for years. Yet many people struggle to take a pill every day because of stigma, forgetfulness, or unstable housing. A twice-yearly injection removes that daily burden almost entirely. It also offers a more discreet form of protection, which can be crucial for people who cannot safely keep pills at home or carry them to work.
What the science shows
Clinical trials produced striking results, with lenacapavir showing near-total protection against HIV in cisgender women. Studies also found it markedly more effective than daily oral PrEP in real-world adherence terms.
Those findings have made the drug a centrepiece of global HIV-prevention strategy. International agencies have urged governments and the manufacturer to make it widely accessible rather than a treatment only for the wealthy.
The term “subcutaneous” simply means the injection goes into the fatty tissue just under the skin, not deep into a muscle. That makes it quicker and often less painful than many people expect. For a patient, the practical difference is enormous: two brief appointments a year instead of 365 daily decisions.
Brazil’s regulatory green light
Brazil’s health regulator, Anvisa, approved lenacapavir in January 2026 for adults and adolescents older than 12 who weigh at least 35 kilograms. The approval cleared the drug for use in the country, but not automatically for free distribution.
Brazil has long been praised for its public HIV response, which offers free testing and treatment through the SUS. Bringing a cutting-edge prevention tool into that system would extend a decades-long commitment to universal access.
Anvisa’s role is to confirm that a medicine is safe and effective. That is a separate step from deciding whether the government will buy and distribute it. Many drugs approved by Anvisa never enter the SUS because they fail the later cost-benefit analysis. The weight threshold of 35 kilograms is a standard safety measure; it ensures the dose is appropriate for a person’s body size, which is why younger or smaller adolescents are excluded for now.
The road into the SUS
Before lenacapavir can be offered free of charge, Brazil’s drug-pricing chamber, CMED, must set a maximum price. The technology commission Conitec and the Ministry of Health will then assess whether to incorporate it into the SUS.
That process weighs clinical benefit against cost and budget impact. It is the standard gateway through which new medicines enter Brazil’s public system.
CMED, the Medicines Market Regulation Chamber, exists precisely to stop drug companies from charging the SUS far more than a medicine is worth. Conitec, the National Commission for the Incorporation of Technologies, then examines whether the drug delivers enough health gain to justify its price tag across a population of over 200 million people. This two-step review is designed to keep the system financially sustainable while still embracing innovation.
The cost question
The biggest obstacle is price. Advocates warn that the drug’s high cost could keep it out of the SUS, deepening inequalities in who can protect themselves from HIV.
LGBTQIA+ organisations and international bodies have pressed for equitable access and lower prices. How Brazil negotiates the cost will shape whether long-acting PrEP reaches the communities that need it most.
This tension is not unique to Brazil. New medicines often launch at prices that strain even wealthy health systems. What makes the debate especially urgent here is Brazil’s constitutional right to health, which guarantees free universal coverage. If a proven prevention tool exists but stays out of reach because of cost, it creates a painful gap between the country’s legal promise and the reality on the ground.
What comes next
Brazil has launched an implementation study of lenacapavir across several cities to test how it works in practice. The research, run with international partners, will help guide any nationwide rollout.
For residents and foreigners who rely on the SUS, the outcome will determine whether a twice-yearly HIV shot becomes freely available. A positive decision would put Brazil among the first countries to offer the tool through a public system.
Several open questions will shape the months ahead. Will CMED set a price ceiling low enough to make a Conitec approval viable? Can Brazil use its purchasing power and history of generic-drug production to negotiate a better deal? And will the implementation study surface any practical hurdles—such as cold-chain storage or training needs—that could slow a national rollout? The answers will determine not just whether lenacapavir enters the SUS, but how quickly and fairly it reaches the people who stand to benefit most.
Frequently Asked Questions
What is lenacapavir?
Lenacapavir is a long-acting HIV pre-exposure prophylaxis (PrEP) given as a subcutaneous injection once every six months, instead of a daily pill.
Has Brazil approved it?
Yes. Anvisa approved lenacapavir in January 2026 for adults and adolescents over 12 weighing at least 35 kg, though free distribution through the SUS is still under review.
Why might it not reach everyone?
Its high cost could block incorporation into the SUS; the price ceiling set by CMED and a Conitec review will determine free access.
Sources
Read More from The Rio Times